Nebulizer Market

Nebulizer Market Size (2023 to 2028)

The global nebulizer market size is forecasted to value USD 1.54 billion by 2028 from USD 1.05 billion in 2023, growing at a CAGR of 7.84% during the forecast period. 

MARKET DRIVERS:

The growing burden of chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis and the increasing adoption of a sedentary lifestyle are propelling the growth of the global nebulizer market.

According to the World Health Organization (WHO) statistics, an estimated 262 million people lived with asthma in 2019, and 455,000 died. COPD is causing a significant number of mortalities across the world. According to American Lung Association, 12.5 million adults in the United States suffer from COPD. According to WHO, 3.23 million people died due to COPD in 2019. Cystic fibrosis is one of the notable genetic diseases in the United States. According to American Lung Association, 30,000 people from the U.S. and an estimated 70,000 worldwide live with cystic fibrosis. COPD accounts for 60% of total respiratory diseases worldwide. In addition, YOY growth in population, the rise in air pollution levels causing breathing difficulties, and the growing population who smoke in developing economies are expected to escalate the incidence of respiratory diseases in emerging countries, which is expected to reflect in the greater demand for nebulizers. Moreover, the changes in the asthma pattern with age and the rise in the incidence of childhood asthma are likely to boost the usage of nebulizers and promote market growth. Furthermore, the growing emphasis of market participants on R&D activities to introduce innovative products is expected to boost the global nebulizer market growth.

In addition, the increasing initiatives and funding from governments and reimbursement policies to promote early diagnosis and treatment are expected to favor the market’s growth rate. For instance, the European Union spends almost 8% of the healthcare budget on managing respiratory diseases yearly. Moreover, the increasing costs with hospitals and other healthcare facilities have promoted the adoption of nebulizers. The use of portable nebulizers also drives the market. Emerging markets such as the Asia Pacific region are anticipated to showcase promising growth opportunities for the market participants.

MARKET RESTRAINTS:

The fierce competition from alternative solutions for nebulizers is expected to hamper the market’s growth rate. Inhalers are easy to use and cost-effective; hence the adoption of inhalers is increasing, which is expected to impact the nebulizer market growth negatively. Moreover, the wastage of drugs in nebulizer therapy is another notable challenge to the growth of the nebulizer market.

Impact of COVID-19 on the global nebulizers market:

The World Health Organization (WHO) announced COVID-19 as an emergency public health issue. Due to the COVID-19 pandemic, the demand for respiratory devices such as nebulizers has grown significantly and favored market growth. During the COVID-19 pandemic, many infected patients suffered from severe respiratory problems, fuelling the demand for nebulizers. With the growing number of COVID-19 patients, the growth rate of the nebulizer market increased. At the same time, many countries have faced shortage of medical supplies such as ventilators, PPEs, needles, and respiratory devices. The patients who were of the risks involved, such as the spread of the coronavirus with the consumption of the nebulizers, have stayed away from using nebulizers, and many governments-imposed restrictions on the usage of medical devices such as nebulizers, which behaved negatively on the market growth. Overall, the global nebulizer market had a mixed impact on the COVID-19 pandemic. However, the nebulizer market is anticipated to register a healthy CAGR during the forecast period.

REPORT COVERAGE:

This research report on the global Nebulizer Market has been segmented and sub-segmented based on the product, modality, end-user, and region.

Nebulizer Market – By Product:

• Jet Nebulizer
• Mesh Nebulizer
• Ultrasonic Nebulizer

The mesh nebulizer segment is predicted to hold a considerable share of the global market during the forecast period owing to the growing adoption of technological advancements in manufacturing these devices. In addition, mesh nebulizers are portable and easy to use, further boosting the adoption and favoring the segment's growth.

The ultrasonic nebulizer segment is anticipated to register a steady CAGR during the forecast period.

Nebulizer Market – By Modality:

• Portable
• Table-top

Based on modality, the tabletop devices segment is forecasted to lead the global market during the forecast period. The benefits associated with table-top devices and the increased market participants with a greater portfolio of table-top devices favor the growth of the table-top segment.

The portable segment is estimated to witness a healthy CAGR during the forecast period. This is because portable devices can be used at home and are easy to use, which promotes the demand for these products and results in the segment's growth. In addition, the growing aging population and increasing demand for traditional treatments are expected to fuel the segment’s growth rate. According to the World Aging 2019 report of the United Nations, the aging population worldwide is anticipated to reach 1.5 billion by 2050.

Nebulizer Market – By End-User:

• Hospitals
• Clinics
• Home care settings

Nebulizer Market – By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

The North American region captured 36.4% global market share in 2021 and is expected to showcase a healthy growth rate during the forecast period owing to the growing volume of patients suffering respiratory diseases, increasing efforts of various governments, favorable reimbursement policies, growing awareness among people regarding the usage of nebulizers and well-established healthcare infrastructure. In addition, the growing adoption of technological developments in manufacturing nebulizers is further propelling regional market growth. Countries such as the U.S. and Canada contributed significantly to the North American region and helped North America register its domination in the global market. The U.S. nebulizer market is estimated to grow at a CAGR of 7.42% from 2022 to 2027. The market growth in the United States is attributed to favorable reimbursement policies, technological advancements, and the presence of key market players.

However, the Asia Pacific nebulizer market is estimated to be the fastest-growing regional market worldwide over the forecast period due to the growing geriatric population, increasing focus on preventive care, and government initiatives promoting technological innovations. China recorded the largest share of the APAC market in 2021.

The European nebulizer market is forecasted to rise at a CAGR of 9.08% from 2022 to 2027. The growing adoption of nebulizers in multiple applications, such as postoperative and delivery rooms and care units for respiratory devices, propels market growth in Europe.

On the other hand, the Latin American nebulizer market is expected to showcase a healthy CAGR during the forecast period. In this region, Brazil, followed by Mexico, is expected to register prominent growth in the future. This is because a large population base in Brazil is affected by pulmonary disorders, such as asthma and COPD, requiring management nebulizers.  

The nebulizer market in the MEA region is predicted to grow at a moderate CAGR from 2022 to 2027.

KEY MARKET PLAYERS:

In this report, the most promising companies that dominate the global nebulizer market are Briggs Healthcare, Besco Medical, Ca-Mi, De Vilbiss Healthcare, Feellife Health, Flyp, Invacare, Omron, Philips Respironics, and Pari Medical.

RECENT MARKET DEVELOPMENTS:

• In November 2022, The Symbicort patent held by AstraZeneca, U.S. Patent No. 10,166,247, was ruled to be invalid by the U.S. District Court for the Northern District of West Virginia, according to an announcement made by Viatris Inc., a multinational healthcare corporation, and Kindeva Drug Delivery L.P. Insufficient written description and lack of enablement were the two grounds on why the district court found the invention to be invalid. Nevertheless, they are eager to have the chance to offer more reasonably priced treatments and already have FDA approval for our generic Symbicort product.
• In November 2022, Shares of CanSino Biologics increased when the company's inhaled Covid-19 vaccination became available as a booster dosage in numerous provincial-level locations in China, including Beijing and Shanghai. The Shanghai-listed stock of the vaccine manufacturer, SHA: 688185, surged as much as 8% before closing the day, 6.5 percent higher at CNY238.58 (USD32.52). CanSino's shares [HKG: 6185] increased 4.9 percent to close at HKD120 in Hong Kong (USD 15.34).
• In October 2022, Together, AeroRx Therapeutics, LLC and HCmed Innovations Co., Ltd. developed a LABA/LAMA combination solution that may be administered using a breath-activated nebulizer. Through this partnership, the two businesses will establish the guidelines for their joint development of a novel nebulized combination formulation for managing chronic obstructive pulmonary disease (COPD).
  In October 2022, according to Richmond Business Sense, Qnovia collected $17 million to continue the development of its RespiRx nicotine replacement medicine. Respir is a powered, portable, hand-held nebulizer that works similarly to an inhaler to deliver medication as an inhaled mist. The gadget is made to hit nicotine faster than other therapies, allowing users to manage withdrawal symptoms better and, as a result, boost their chances of quitting smoking.